Sign in
4

Changes in Ownership

CytomX Therapeutics, Inc. Filed Acc 0001140361-17-021016

Chief Financial Officer acquired 19,967 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Goeltz II Robert C. · Chief Financial Officer

Table I: Non-derivative

2 lines
Date Transaction Shares Price Value Owned after D/I
2017-05-12 Exercise or conversion : show line 1 in the form +9,980 $4.47 $44,639 22,769 D
2017-05-12 Exercise or conversion : show line 2 in the form +9,987 $6.61 $66,061 32,756 D

Table II: Derivative

2 lines
Date Transaction Shares Owned after D/I
2017-05-12 Exercise or conversion : show line 3 in the form Stock Option (Right to Buy) −9,980 204,678 D
2017-05-12 Exercise or conversion : show line 4 in the form Stock Option (Right to Buy) −9,987 85,891 D
Loading xslF345X03/doc1.xml…